How I Found My Balance With Exercise
Exercise can be tricky when you have myasthenia gravis. Climbing a mountain is even trickier, but one woman did. Here’s her story. (Source: WebMD Health)
Source: WebMD Health - July 17, 2023 Category: Consumer Health News Source Type: news
Changing My Pace With Myasthenia Gravis
If you have myasthenia gravis, you may wonder how to manage your fatigue. One woman shares how she balances everything. (Source: WebMD Health)
Source: WebMD Health - July 17, 2023 Category: Consumer Health News Source Type: news
How to Prioritize Your Well-being With Myasthenia Gravis
Living with myasthenia gravis can take a toll on your mental, and physical health. Read one woman’s story about how to manage well-being with myasthenia gravis. (Source: WebMD Health)
Source: WebMD Health - July 14, 2023 Category: Consumer Health News Source Type: news
Adapted CAR-T Therapy Shows Promise in Myasthenia Gravis
(MedPage Today) -- The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T) therapy in autoimmune disease showed people with generalized myasthenia gravis tolerated the treatment well and experienced improvements in disease... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 8, 2023 Category: Neurology Source Type: news
Early Success: mRNA & CAR T Therapy To Treat Rare Autoimmune Disease Myasthenia Gravis
A small clinical trial demonstrates encouraging early results using an adopted version of CAR T therapy to treat patients with rare autoimmune disorder myasthenia gravis. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 7, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
FDA Greenlights New Myasthenia Gravis Drug
(MedPage Today) -- The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday.
The drug is the first approved to treat both of the two most... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 27, 2023 Category: American Health Source Type: news
FDA Approves Rystiggo (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis
Brussels (Belgium) June 27 2023– UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced Rystiggo® (rozanolixizumab-noli)* has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2023 Category: Drugs & Pharmacology Source Type: news
Myasthenia Gravis Drug Gets FDA Nod Myasthenia Gravis Drug Gets FDA Nod
The monoclonal antibody rozanolixizumab (Rystiggo) is indicated to treat adults with the two most common subtypes of generalized myasthenia gravis.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 27, 2023 Category: Primary Care Tags: Neurology & Neurosurgery News Alert Source Type: news
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has recommended for marketing authorization of AstraZeneca Plc's AZN Soliris (eculizumab) for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. gMG is a rare, chronic autoimmune neuromuscular disease causing severe weakness and loss of…#astrazenecaplc #aznsoliris #soliris #qmg #fda #argenxse #argx #vyvgarthytrulo #azn (Source: Reuters: Health)
Source: Reuters: Health - June 26, 2023 Category: Consumer Health News Source Type: news
Episode 1: Myasthenia Gravis: Which Test Is Best? When and Why? Episode 1: Myasthenia Gravis: Which Test Is Best? When and Why?
Drs Nicholas Silvestri and Carolina Barnett-Tapia discuss what you need to know about immunopathogenesis and diagnosis for this relatively rare condition.Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 22, 2023 Category: Intensive Care Tags: Neurology & Neurosurgery InDiscussion Source Type: news
Episode 2: Treating Myasthenia Gravis? Don't Stop at Pyridostigmine Episode 2: Treating Myasthenia Gravis? Don't Stop at Pyridostigmine
Drs Nicholas Silvestri and Neelam Goyal lay out pathways for successful routine treatment of myasthenia gravis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery InDiscussion Source Type: news
Potential treatment for rare autoimmune disorder adapted from CAR-T therapy
NIH-supported trial first step in developing new approach to treat myasthenia gravis. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 22, 2023 Category: American Health Source Type: news
FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use in Generalized Myasthenia Gravis
SAN DIEGO, June 20, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( " Halozyme " ) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 20, 2023 Category: Drugs & Pharmacology Source Type: news
Planning Financially for Myasthenia Gravis
Myasthenia gravis finances: What to expect, what to plan for, how to navigate insurance, where to find financial assistance. (Source: WebMD Health)
Source: WebMD Health - June 1, 2023 Category: Consumer Health News Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
